| Species |
Human |
| Protein Construction |
IL-1 R9 (Thr17-Lys354)
Accession # Q9NP60 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
65.66 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 75-95 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The interleukin 1 receptor (IL-1R) and the Toll-like receptors (TLRs) are highly homologous innate immune receptors that provide the first line of defense against infection. IL-1R have appeared for functions that do not require IL-1 ligand binding is supported by the case of the orphan receptors IL-1R10 and IL-1R9, which do not have known ligands and that have non-immune functions in the brain. |
| Synonyms |
IL-1-RAPL-2; IL-1RAPL-2; IL1RAPL-2; IL-1R-9; IL-1R9; TIGIRR-1; IL1RAPL2; IL1R9 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
